Barclays
TXG icon

Barclays’s 10x Genomics TXG Stock Holding History

Barclays’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,500
Closed -$340K – 5484
2024
Q2 		$340K Buy
+17,500
New +$458K ﹤0.01% 3271

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's TXG Position: Q1 2026 in Review

Barclays reduced its 10x Genomics (TXG) stake by 91% in Q1 2026, selling an estimated $5.78M and leaving 29,098 shares worth $618K. The position accounts for ﹤0.01% of the portfolio, ranked #3062.

Barclays first reported a position in TXG in Q1 2022 and has held it in 17 quarters since. The position peaked at $14.9M in Q4 2023. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Barclays held 29,098 shares of 10x Genomics worth $618K as of Q1 2026.
  • Barclays sold 288,884 10x Genomics shares in Q1 2026, an estimated $5.78M.
  • 10x Genomics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3062 holding.
  • Barclays first reported a position in 10x Genomics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's 10x Genomics position peaked at $14.9M in Q4 2023.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.